Details for New Drug Application (NDA): 022192
✉ Email this page to a colleague
NDA 022192 describes FANAPT, which is a drug marketed by Vanda Pharms Inc and is included in one NDA. It is available from one supplier. There are eight patents protecting this drug and one Paragraph IV challenge. Additional details are available on the FANAPT profile page.
The generic ingredient in FANAPT is iloperidone. There are eight drug master file entries for this compound. Two suppliers are listed for this compound. Additional details are available on the iloperidone profile page.
The generic ingredient in FANAPT is iloperidone. There are eight drug master file entries for this compound. Two suppliers are listed for this compound. Additional details are available on the iloperidone profile page.
Summary for 022192
| Tradename: | FANAPT |
| Applicant: | Vanda Pharms Inc |
| Ingredient: | iloperidone |
| Patents: | 8 |
DrugPatentWatch® Estimated Loss of Exclusivity (LOE) Date for 022192
Generic Entry Date for 022192*:
Constraining patent/regulatory exclusivity:
Dosage:
TABLET;ORAL |
*The generic entry opportunity date is the latter of the last compound-claiming patent and the last regulatory exclusivity protection. Many factors can influence early or later generic entry. This date is provided as a rough estimate of generic entry potential and should not be used as an independent source.
Pharmacology for NDA: 022192
Suppliers and Packaging for NDA: 022192
| Tradename | Generic Name | Dosage | NDA | Application Type | Supplier | National Drug Code | Package Code | Package |
|---|---|---|---|---|---|---|---|---|
| FANAPT | iloperidone | TABLET;ORAL | 022192 | NDA | Vanda Pharmaceuticals Inc. | 43068-101 | 43068-101-02 | 60 TABLET in 1 BOTTLE (43068-101-02) |
| FANAPT | iloperidone | TABLET;ORAL | 022192 | NDA | Vanda Pharmaceuticals Inc. | 43068-102 | 43068-102-02 | 60 TABLET in 1 BOTTLE (43068-102-02) |
Profile for product number 001
| Active Rx/OTC/Discontinued: | RX | Dosage: | TABLET;ORAL | Strength | 1MG | ||||
| Approval Date: | May 6, 2009 | TE: | RLD: | Yes | |||||
| Regulatory Exclusivity Expiration: | Apr 2, 2027 | ||||||||
| Regulatory Exclusivity Use: | INDICATED FOR ACUTE TREATMENT OF MANIC OR MIXED EPISODES ASSOCIATED WITH BIPOLAR I DISORDER IN ADULTS | ||||||||
| Patent: | ⤷ Start Trial | Patent Expiration: | Nov 2, 2027 | Product Flag? | Substance Flag? | Delist Request? | |||
| Patented Use: | METHOD OF TREATING SCHIZOPHRENIA BY ADMINISTERING ILOPERIDONE TO A PATIENT BY REDUCING THE DOSE IN PATIENTS WHO ARE POOR METABOLIZERS OF CYP2D6 | ||||||||
| Patent: | ⤷ Start Trial | Patent Expiration: | Aug 31, 2030 | Product Flag? | Substance Flag? | Delist Request? | |||
| Patented Use: | DOSAGE MODIFICATION TO REDUCE THE RISK ASSOCIATED WITH QT PROLONGATION NOT INDUCED BY OTHER DRUGS DURING TREATMENT WITH ILOPERIDONE | ||||||||
Expired US Patents for NDA 022192
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | Patent No. | Patent Expiration |
|---|---|---|---|---|---|---|---|
| Vanda Pharms Inc | FANAPT | iloperidone | TABLET;ORAL | 022192-006 | May 6, 2009 | ⤷ Start Trial | ⤷ Start Trial |
| Vanda Pharms Inc | FANAPT | iloperidone | TABLET;ORAL | 022192-002 | May 6, 2009 | ⤷ Start Trial | ⤷ Start Trial |
| Vanda Pharms Inc | FANAPT | iloperidone | TABLET;ORAL | 022192-006 | May 6, 2009 | ⤷ Start Trial | ⤷ Start Trial |
| Vanda Pharms Inc | FANAPT | iloperidone | TABLET;ORAL | 022192-001 | May 6, 2009 | ⤷ Start Trial | ⤷ Start Trial |
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >Patent No. | >Patent Expiration |
Complete Access Available with Subscription
